



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

11 June 2025
EMA/CAT/197609/2025
Human Medicines Division

Committee for Advanced Therapies (CAT)

Draft agenda for the meeting on 11-13 June 2025

Chair: Ilona Reischl; Vice-Chair: Kieran Breen

11 June 2025, 14:00 – 18:30

12 June 2025, 09:00 – 18:30

13 June 2025, 09:00 – 13:00

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CAT meeting reports once the procedures are finalised.

Of note, this agenda is a working document primarily designed for CAT members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to ongoing procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).



Table of contents

1.	Introduction	5
1.1.	Welcome and declarations of interest of members, alternates and experts.....	5
1.2.	Adoption of agenda	5
1.3.	Adoption of the minutes	5
2.	Evaluation of ATMPs	5
2.1.	Opinions	5
2.1.1.	Dorocubicel / Allogeneic umbilical cord-derived CD34- cells, non-expanded - PRIME - Orphan - EMEA/H/C/005772.....	5
2.2.	Oral explanations	5
2.2.1.	Delandistrogene moxeparvovec - Orphan - EMEA/H/C/005293	5
2.2.2.	Autologous cartilage-derived articular chondrocytes, in-vitro expanded - EMEA/H/C/0045946	
2.3.	Day 180 list of outstanding issues	6
2.3.1.	Mozafancogene autotemcel - PRIME - Orphan - EMEA/H/C/005537	6
2.4.	Day 120 list of questions	6
2.5.	Day 80 assessment reports	6
2.6.	Update on ongoing initial applications.....	6
2.7.	New applications	6
2.7.1.	In vitro diagnostic medical device - EMEA/H/D/006768	6
2.7.2.	Onasemnogene abeparvovec - Orphan - EMEA/H/C/6498	6
2.8.	Withdrawal of initial marketing authorisation application	7
2.9.	Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004	7
2.10.	GMP and GCP inspections requests.....	7
2.11.	Type II variations and variations of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008	7
2.11.1.	Tecartus - Brexucabtagene autoleucel - Orphan - EMEA/H/C/005102/II/0051	7
2.11.2.	Casgevy - Exagamglogene autotemcel - Orphan - EMA/VR/0000264854.....	7
2.11.3.	CARVYKTI - Ciltacabtagene autoleucel - Orphan - EMA/VR/0000264849	7
2.11.4.	CARVYKTI - Ciltacabtagene autoleucel - Orphan - EMA/VR/0000264446	8
2.11.5.	Breyanzi - Lisocabtagene maraleucel - Orphan - EMA/VR/0000264124	8
2.11.6.	Breyanzi - Lisocabtagene maraleucel - Orphan - EMA/VR/0000258227	8
2.11.7.	Imlygic - Talimogene laherparepvec - Orphan - EMA/VR/0000258245	9
2.11.8.	Abecma - Idecabtagene vicleucel - Orphan - EMA/VR/0000249089	9
2.11.9.	Abecma - Idecabtagene vicleucel - Orphan - EMA/VR/0000248772	9
2.12.	Extension applications.....	9
2.13.	Other Post-Authorisation Activities	9
2.13.1.	Ebvallo - Tabelecleucel - Orphan - EMA/S/0000249324	9

2.13.2.	Casgevvy - Exagamglogene autotemcel - Orphan - EMA/PAM/0000266956.....	9
2.13.3.	Casgevvy - Exagamglogene autotemcel - Orphan - EMA/PAM/0000266953.....	10
2.13.4.	Casgevvy - Exagamglogene autotemcel - Orphan - EMA/PAM/0000266952.....	10
2.13.5.	Casgevvy - Exagamglogene autotemcel - Orphan - EMA/PAM/0000266949.....	10
2.13.6.	Casgevvy - Exagamglogene autotemcel - Orphan - EMA/PAM/0000266947.....	10
2.13.7.	Casgevvy - Exagamglogene autotemcel - Orphan - EMA/PAM/0000266944.....	10
2.13.8.	Casgevvy - Exagamglogene autotemcel - Orphan - EMA/PAM/0000266941.....	10
2.13.9.	CARVYKTI - Ciltacabtagene autoleucel - Orphan - EMA/PAM/0000265655.....	11
2.13.10.	Breyanzi - Lisocabtagene maraleucel - Orphan - EMA/PAM/0000265380.....	11
2.13.11.	Hemgenix - Etranacogene dezaparvovec - Orphan - EMA/PAM/0000264977.....	11
2.13.12.	BEQVEZ - Fidanacogene elaparvovec - Orphan - EMA/PAM/0000262832.....	11
2.13.13.	Kymriah – Tisagenlecleucel - EMA/PAM/0000258545.....	11
2.14.	Companion diagnostics - initial consultation	12
2.15.	Companion diagnostics – Follow-up consultation	12

3. Certification of ATMPs 12

3.1.	Opinion.....	12
3.2.	Day 60 Evaluation Reports.....	12
3.3.	New Applications.....	12

4. Scientific Recommendation on Classification of ATMPs 12

4.1.	New requests – Appointment of CAT Coordinator	12
4.1.1.	Allogeneic human midbrain dopaminergic neuron (mDA) progenitor cells derived from human pluripotent stem cells.....	12
4.1.2.	Cell-free extracellular matrix derived from decellularized porcine skin tissue and cell-free concentrated secretome from human adipose-derived stromal cells	13
4.1.3.	Bone-marrow and/or adipose tissue derived mesenchymal stem cells, embedded into a 3d non-woven polymer matrix.....	13
4.2.	Day 30 ATMP scientific recommendation	13
4.2.1.	Replication defective SV40 vector encoding for human proinsulin.....	13
4.2.2.	Anitocabtagene autoleucel	13
4.3.	Day 60 revised scientific recommendation (following list of questions)	13
4.4.	Finalisation of procedure	13
4.4.1.	Human oocyte cytoplasm.....	13
4.4.2.	Selected autologous Tumor-Infiltrating Lymphocytes (TILs) isolated from tumor tissue, lymph node metastases, or peripheral blood, expanded, activated	14
4.4.3.	Autologous T cells ex vivo transduced with LVV encoding a CAR that recognises BCMA.....	14
4.4.4.	Genetically modified porcine heart	14
4.5.	Follow-up and guidance.....	14

5.	Scientific Advice	14
5.1.	New requests - appointment of CAT Rapporteurs	14
5.1.1.	Ongoing scientific advice procedures - Appointment of CAT Peer Reviewers	14
5.1.2.	Scientific advice procedures starting at the next SAWP meeting	14
5.2.	Procedures discussed at SAWP – 1st reports, D40 JRs, LoIs	15
5.3.	Finalisation of D70 procedures – feedback from the discussion meeting	15
5.4.	Final Advice Letters for procedures finalised the previous month.....	15
6.	Pre-Authorisation Activities	15
6.1.	Paediatric investigation plans.....	15
6.2.	ITF briefing meetings in the field of ATMPs	15
6.3.	Priority Medicines (PRIME) – Eligibility requests.....	15
6.3.1.	Month 0 - Start of the procedure	15
6.3.2.	Month 1 – Discussion of eligibility	15
6.3.3.	Month 2 – Recommendation of eligibility.....	15
6.3.4.	Ongoing support.....	16
7.	Organisational, regulatory and methodological matters	16
7.1.	Mandate and organisation of the CAT	16
7.1.1.	CAT membership	16
7.1.2.	Vote by proxy	16
7.1.3.	EMA Committee Reform.....	16
7.1.4.	CAT Dates (online & face2face) 2026	16
7.2.	Coordination with EMA Scientific Committees.....	16
7.3.	Coordination with EMA Working Parties/Working Groups/Drafting Groups	16
7.3.1.	BWP/CAT Learning on Claims for New Active Substance (NAS) status for ATMPs.....	16
7.4.	Cooperation with the EU regulatory network.....	16
7.5.	Cooperation with international regulators.....	17
7.5.1.	ATMP cluster teleconference with US-FDA, Health Canada, PMDA (Japan) and Swissmedic	17
7.5.2.	ICH Cell & Gene Therapy Discussion Group (CGTDG) - upcoming consultation on draft recommendations on future ATMP-related guidelines.....	17
7.6.	CAT work plan	17
7.6.1.	CAT work plan 2025.....	17
7.7.	Planning and reporting	17
7.8.	Others	17
7.8.1.	EMA survey: exploring the role of Patient Preference Studies in the Benefit/Risk assessment	17
8.	Any other business	17
9.	Explanatory notes	19

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CAT plenary session to be held 11-13 June 2025. See June 2025 CAT minutes (to be published post July 2025 CAT meeting).

1.2. Adoption of agenda

CAT agenda for 11-13 June 2025 meeting

1.3. Adoption of the minutes

CAT minutes for 14-16 May 2025 meeting

2. Evaluation of ATMPs

2.1. Opinions

2.1.1. Dorocubicel / Allogeneic umbilical cord-derived CD34- cells, non-expanded - PRIME - Orphan - EMEA/H/C/005772

Cordex Biologics International Limited; Treatment of adult patients with haematological malignancies

Scope: Opinion

Action: for adoption

List of outstanding issues adopted on 21.03.2025. List of questions adopted on 11.10.2024.

2.2. Oral explanations

2.2.1. Delandistrogene moxeparvovec - Orphan - EMEA/H/C/005293

Roche Registration GmbH; Treatment of ambulatory patients aged 3 to 7 years old with Duchenne muscular dystrophy

Scope: Oral explanation

Action: Oral explanation

List of questions adopted on 11.10.2024. List of outstanding issues adopted 14.05.2025.

2.2.2. Autologous cartilage-derived articular chondrocytes, in-vitro expanded - EMEA/H/C/004594

Repair of symptomatic, localised, full-thickness cartilage defects of the knee joint grade III or IV

Scope: Oral explanation

Action: Oral explanation

List of questions adopted on 19.04.2024. List of outstanding issues adopted 19.03.2025.

2.3. Day 180 list of outstanding issues

2.3.1. Mozafancogene autotemcel - PRIME - Orphan - EMEA/H/C/005537

Rocket Pharmaceuticals B.V.; Treatment of paediatric patients with Fanconi anaemia type A

Scope: Day 180 list of outstanding issues

Action: for adoption

List of questions adopted on 19.07.2024.

2.4. Day 120 list of questions

No items

2.5. Day 80 assessment reports

No items

2.6. Update on ongoing initial applications

No items

2.7. New applications

2.7.1. In vitro diagnostic medical device - EMEA/H/D/006768

Qualitative determination of antibodies to adeno-associated virus serotype 74 (AAVrh74) in human serum and/or plasma

Scope: Timetable for assessment

Action: for adoption

2.7.2. Onasemnogene abeparvovec - Orphan - EMEA/H/C/6498

Novartis Europharm Limited; Treatment of patients with 5q spinal muscular atrophy

(SMA)Scope: Timetable for assessment

Action: for adoption

2.8. Withdrawal of initial marketing authorisation application

No items

2.9. Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004

No items

2.10. GMP and GCP inspections requests

No items

2.11. Type II variations and variations of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

2.11.1. Tecartus - Brexucabtagene autoleucel - Orphan - EMEA/H/C/005102/II/0051

Kite Pharma EU B.V.

Rapporteur: Jan Mueller-Berghaus; PRAC Rapporteur: Bianca Mulder

Scope: Clinical, PRAC led

Submission of the final study report for the non-interventional study KT-EU-472-5966 titled "Quantitative Testing of Health Care Professional Knowledge About Tecartus Risk Minimisation Measures" listed as a category 3 study in the RMP.

Action: for adoption

Request for supplementary information adopted on 06.12.2024.

2.11.2. Casgevy - Exagamglogene autotemcel - Orphan - EMA/VR/0000264854

Vertex Pharmaceuticals (Ireland) Limited

Rapporteur: Jan Mueller-Berghaus, Co-rapporteur: Heli Suila; PRAC Rapporteur: Bianca Mulder

Scope: Quality

Action: for adoption

2.11.3. CARVYKTI - Ciltacabtagene autoleucel - Orphan - EMA/VR/0000264849

Janssen-Cilag International NV

Rapporteur: Jan Mueller-Berghaus

Scope: Quality

Action: for adoption

2.11.4. CARVYKTI - Ciltacabtagene autoleucel - Orphan - EMA/VR/0000264446

Janssen-Cilag International NV

Rapporteur: Jan Mueller-Berghaus

Scope: Clinical, request for supplementary information

Update of section 4.4 of the SmPC in order to amend an existing warning on secondary malignancies including of T-cell origin to limit the testing only to secondary malignancy of T-cell origin based on the data from clinical studies and literature.

Action: for adoption

2.11.5. Breyanzi - Lisocabtagene maraleucel - Orphan - EMA/VR/0000264124

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Concetta Quintarelli

Scope: Clinical, request for supplementary information

A grouped application consisting of:

C.I.4: Update of section 5.1 of the SmPC in order to update efficacy information based on final results from study JCAR017-BCM-003; this is a global randomised multicenter phase 3 trial to compare the efficacy and safety of JCAR017 to standard of care in adult subjects with high-risk, transplant-eligible relapsed or refractory aggressive B-cell Non-Hodgkin lymphomas (TRANSFORM). In addition, final study reports for studies 017006 and JCAR017-BCM-001 Cohort 2 are submitted to support the main scope.

C.I.4: Update of section 4.8 of the SmPC in order to update information for the safety and immunogenicity based on pooled final data from the three follow up studies: (TRANSFORM BCM-003, PILOT 17006 and TRANSCEND WORLD, cohort 2 BCM-001). In addition, the MAH took the opportunity to remove the dose verification worksheet statement from the Labelling.

Action: for adoption

2.11.6. Breyanzi - Lisocabtagene maraleucel - Orphan - EMA/VR/0000258227

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Concetta Quintarelli

Scope: Quality, request for supplementary information

Action: for adoption

[2.11.7. Imlygic - Talimogene laherparepvec - Orphan - EMA/VR/0000258245](#)

Amgen Europe B.V.

Rapporteur: Maija Tarkkanen

Scope: Quality, request for supplementary information

Action: for adoption

[2.11.8. Abecma - Idecabtagene vicleucel - Orphan - EMA/VR/0000249089](#)

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Rune Kjekken

Scope: Quality, request for supplementary information

Action: for adoption

[2.11.9. Abecma - Idecabtagene vicleucel - Orphan - EMA/VR/0000248772](#)

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Rune Kjekken

Scope: Quality, opinion

Action: for adoption

2.12. Extension applications

No items

2.13. Other Post-Authorisation Activities

[2.13.1. Ebvallo - Tabelecleucel - Orphan - EMA/S/0000249324](#)

Pierre Fabre Medicament

Rapporteur: Egbert Flory

Scope: Second annual re-assessment in the frame of a marketing authorisation under exceptional circumstances, opinion

Action: for adoption

[2.13.2. Casgevy - Exagamglogene autotemcel - Orphan - EMA/PAM/0000266956](#)

Vertex Pharmaceuticals (Ireland) Limited

Rapporteur: Jan Mueller-Berghaus

Scope: PAM, quality

Action: for adoption

2.13.3. [Casgevy - Exagamglogene autotemcel - Orphan - EMA/PAM/0000266953](#)

Vertex Pharmaceuticals (Ireland) Limited

Rapporteur: Jan Mueller-Berghaus

Scope: PAM, quality

Action: for adoption

2.13.4. [Casgevy - Exagamglogene autotemcel - Orphan - EMA/PAM/0000266952](#)

Vertex Pharmaceuticals (Ireland) Limited

Rapporteur: Jan Mueller-Berghaus

Scope: PAM, quality

Action: for adoption

2.13.5. [Casgevy - Exagamglogene autotemcel - Orphan - EMA/PAM/0000266949](#)

Vertex Pharmaceuticals (Ireland) Limited

Rapporteur: Jan Mueller-Berghaus

Scope: PAM, quality

Action: for adoption

2.13.6. [Casgevy - Exagamglogene autotemcel - Orphan - EMA/PAM/0000266947](#)

Vertex Pharmaceuticals (Ireland) Limited

Rapporteur: Jan Mueller-Berghaus

Scope: PAM, quality

Action: for adoption

2.13.7. [Casgevy - Exagamglogene autotemcel - Orphan - EMA/PAM/0000266944](#)

Vertex Pharmaceuticals (Ireland) Limited

Rapporteur: Jan Mueller-Berghaus

Scope: PAM, quality

Action: for adoption

2.13.8. [Casgevy - Exagamglogene autotemcel - Orphan - EMA/PAM/0000266941](#)

Vertex Pharmaceuticals (Ireland) Limited

Rapporteur: Jan Mueller-Berghaus

Scope: PAM, quality

Action: for adoption

2.13.9. [CARVYKTI - Ciltacabtagene autoleucel - Orphan - EMA/PAM/0000265655](#)

Janssen-Cilag International NV

Rapporteur: Jan Mueller-Berghaus

Scope: PAM, quality

Action: for adoption

2.13.10. [Breyanzi - Lisocabtagene maraleucel - Orphan - EMA/PAM/0000265380](#)

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Concetta Quintarelli

Scope: PAM, quality

Action: for adoption

2.13.11. [Hemgenix - Etranacogene dezaparvovec - Orphan - EMA/PAM/0000264977](#)

CSL Behring GmbH

Rapporteur: Silke Dorner

Scope: PAM, quality

Action: for adoption

2.13.12. [BEQVEZ - Fidanacogene elaparovvec - Orphan - EMA/PAM/0000262832](#)

Pfizer Europe MA EEIG

Rapporteur: Jan Mueller-Berghaus

Scope: PAM, quality

Action: for adoption

2.13.13. [Kymriah – Tisagenlecleucel - EMA/PAM/0000258545](#)

Novartis Europharm Limited

Rapporteur: Rune Kjeklen

Scope: PAM, pharmacovigilance

Action: for adoption

2.14. Companion diagnostics - initial consultation

No items

2.15. Companion diagnostics – Follow-up consultation

No items

3. Certification of ATMPs

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

3.1. Opinion

No items

3.2. Day 60 Evaluation Reports

No items

3.3. New Applications

No items

4. Scientific Recommendation on Classification of ATMPs

Timetable:

-Start of the procedure:	16.06.2025
-EMA Coordinator's draft report:	24.06.2025
-CAT Coordinator's comments:	02.07.2025
-Revised scientific recommendation:	11.07.2025
-CAT's discussion of scientific recommendation:	18.07.2025

4.1. New requests – Appointment of CAT Coordinator

4.1.1. Allogeneic human midbrain dopaminergic neuron (mDA) progenitor cells derived from human pluripotent stem cells

Treatment of Parkinson's disease

Scope: Nomination of CAT coordinator

Action: for adoption

4.1.2. [Cell-free extracellular matrix derived from decellularized porcine skin tissue and cell-free concentrated secretome from human adipose-derived stromal cells](#)

Treatment of perianal fistulas

Scope: Nomination of CAT coordinator

Action: for adoption

4.1.3. [Bone-marrow and/or adipose tissue derived mesenchymal stem cells, embedded into a 3d non-woven polymer matrix](#)

Treatment of critical limb ischemia

Scope: Nomination of CAT coordinator

Action: for adoption

4.2. **Day 30 ATMP scientific recommendation**

4.2.1. [Replication defective SV40 vector encoding for human proinsulin](#)

Treatment of type 1 diabetes

Scope: ATMP scientific recommendation

Action: for adoption

4.2.2. [Anitocabtagene autoleucel](#)

Treatment of patients with multiple myeloma

Scope: ATMP scientific recommendation

Action: for adoption

4.3. **Day 60 revised scientific recommendation (following list of questions)**

No items

4.4. **Finalisation of procedure**

4.4.1. [Human oocyte cytoplasm](#)

For use in case of low human egg quality in invitro fertilisation (IVF)

Scope: ATMP scientific recommendation. European Commission raised no comments.

Action: for adoption

4.4.2. Selected autologous Tumor-Infiltrating Lymphocytes (TILs) isolated from tumor tissue, lymph node metastases, or peripheral blood, expanded, activated

Treatment of advanced or metastatic solid tumours

Scope: ATMP scientific recommendation. European Commission raised no comments.

Action: for adoption

4.4.3. Autologous T cells ex vivo transduced with LVV encoding a CAR that recognises BCMA

Treatment of relapsed or refractory form of plasmocytic myeloma (RRMM)

Scope: ATMP scientific recommendation. European Commission raised no comments.

Action: for adoption

4.4.4. Genetically modified porcine heart

Intended for cardiac xenotransplantation to human patients with end-stage heart failure

Scope: ATMP scientific recommendation

Action: for adoption

4.5. Follow-up and guidance

No items

5. Scientific Advice

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.1. New requests - appointment of CAT Rapporteurs

5.1.1. Ongoing scientific advice procedures - Appointment of CAT Peer Reviewers

Timetable:

- Start of procedure at SAWP:	02-05.06.2025
- Appointment of CAT Peer Reviewers:	11-13.06.2025
- SAWP first reports:	30.06.2025
- CAT Peer Reviewer comments (NC & C):	04.07.2025
- CAT Peer Reviewer comments (Q):	09.07.2025
- Discussion at SAWP:	07-10.07.2025
- Discussion at CAT and feedback to SAWP:	16-18.07.2025

5.1.2. Scientific advice procedures starting at the next SAWP meeting

Timetable:

- Start of procedure at SAWP:	07-10.07.2025
- Appointment of CAT Peer Reviewers:	16-18.07.2025
- SAWP first reports:	25.08.2025
- CAT Peer Reviewer comments (NC & C):	29.08.2025
- CAT Peer Reviewer comments (Q):	03.09.2025
- Discussion at SAWP:	01-04.09.2025
- Discussion at CAT and feedback to SAWP:	10-12.09.2025

5.2. Procedures discussed at SAWP – 1st reports, D40 JRs, LoIs

5.3. Finalisation of D70 procedures – feedback from the discussion meeting

5.4. Final Advice Letters for procedures finalised the previous month

6. Pre-Authorisation Activities

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6.1. Paediatric investigation plans

No items

6.2. ITF briefing meetings in the field of ATMPs

6.3. Priority Medicines (PRIME) – Eligibility requests

6.3.1. Month 0 - Start of the procedure

Timetable for assessment:	
Procedure start:	02-05.06.2025
SAWP recommendation:	10.07.2025
CAT recommendation:	18.07.2025
CHMP adoption of report and final recommendation:	24.07.2025

6.3.2. Month 1 – Discussion of eligibility

6.3.3. Month 2 – Recommendation of eligibility

6.3.4. Ongoing support

No items

7. Organisational, regulatory and methodological matters

7.1. Mandate and organisation of the CAT

7.1.1. CAT membership

Action: for information

7.1.2. Vote by proxy

Action: for information

7.1.3. EMA Committee Reform

Scope: Brainstorming on the future process for the evaluation of MAAs for ATMPs

Action: for discussion

7.1.4. CAT Dates (online & face2face) 2026

Scope: CAT Plenary 2026 dates

Action: for information

7.2. Coordination with EMA Scientific Committees

No items

7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

7.3.1. BWP/CAT Learning on Claims for New Active Substance (NAS) status for ATMPs

Rapporteur/Coordinator: Sean Barry, Ilona Reischl

Scope: BWP/CAT learning on assessment of NAS claims for ATMPs - updated following MS comments

Action: for discussion

7.4. Cooperation with the EU regulatory network

No items

7.5. Cooperation with international regulators

7.5.1. ATMP cluster teleconference with US-FDA, Health Canada, PMDA (Japan) and Swissmedic

CAT: Ilona Reischl

Scope: Agenda topics for the teleconference of 26.06.2025

Action: for information

7.5.2. ICH Cell & Gene Therapy Discussion Group (CGTDG) - upcoming consultation on draft recommendations on future ATMP-related guidelines

CAT: Jan Muller-Berghaus

Scope: Status update.

Action: for information

7.6. CAT work plan

7.6.1. CAT work plan 2025

CAT: Ilona Reischl

Scope: Tour de table on progress of 2025 CAT workplan activities and feedback on the planned CAT workshop in genome editing.

Action: for discussion

7.7. Planning and reporting

No items

7.8. Others

7.8.1. EMA survey: exploring the role of Patient Preference Studies in the Benefit/Risk assessment

Scope: Reminder to the committee

Action: for discussion

8. Any other business

No items

Date of next CAT meeting:

16-18 July 2025

9. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

For a list of acronyms and abbreviations, see:

[List of abbreviations used in EMA human medicines scientific committees and CMDh documents, and in relation to EMA's regulatory activities](#)


Evaluation of ATMPs (section 2)

This section lists applications for marketing authorisations of new Advanced Therapy Medicinal Products (ATMPs) that are to be discussed by the Committee. It also lists Post-authorisation activities (section 2.11-2.13) and any ATMP related inspection requests (section 2.14).

New applications (sections 2.1. to 2.9.)

Section 2.1 is for ATMPs nearing the end of the evaluation and for which the CAT is expected to adopt a draft **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CAT opinion is transmitted to the CHMP for final adoption. The CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU. More information on the evaluation of ATMPs can be found [here](#).

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CAT. The clock stop happens after day 120 and may also happen after day 180, when the CAT has adopted respectively a **Day 120 list of questions** (section 2.4) or a List of outstanding issues to be addressed by the company, which is listed in the agenda under sections 2.7 (**Ongoing evaluation procedures** (section 2.3)). Section 2.6 also includes the CAT discussions at any other timepoint of the evaluation procedure of new applications.

Oral explanation (section 2.2.)

Prior to adoption of the CAT opinion, marketing authorisation applicants are normally invited to the CAT plenary meeting to address questions raised by the Committee.

Oral explanations normally relate to ongoing applications, but they can also relate to any other issue for which the CAT would like to discuss with company representatives in person.

New applications (section 2.7.)

In this section, information is included on upcoming marketing authorisation applications for ATMPs, as well as information on appointment of Rapporteurs for new ATMP applications.

Withdrawal of applications (section 2.8.)

This section includes information on marketing authorisation applications that are withdrawn by the applicant. Applicants may decide to withdraw applications at any stage during the assessment and a CAT opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (section 2.9.)

This section lists applications for new marketing authorisation for ATMPs for which the applicant has requested a re-examination of the opinion previously issued by the CHMP. Similar to the initial evaluation of a marketing authorisation of an ATMP, CAT will adopt a draft re-examination opinion, which is transmitted to the CHMP for final adoption.

GMP and GCP Inspections Issues (section 2.10.)

This section lists inspections that are undertaken for ATMPs. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Post-authorisation activities (section 2.11-2.13.)

Section 2.11 lists type II variations, including extension of indication applications and re-examination procedures for type II variations for which the applicant has requested re-examination of the opinion previously issued by the CHMP. Section 2.12 list extension application according to Annex I of Reg. 1234/2008 and section 2.13 includes all other post-authorisation activities concerning authorised ATMPs that are not covered elsewhere in the agenda such as post-authorisation measures, annual reassessments, 5-year renewals, supply shortages, qualify defects. Issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines, will also be included here.

Companion diagnostics (section 2.14-2.15)

This section lists applications for initial and follow-on consultation of companion diagnostics.

Certification of ATMPs (section 3)

This section includes the scientific evaluation by the CAT of quality and non-clinical data that small and medium-sized enterprises have generated at any stage of the ATMP development process. More information on the ATMP certification procedure can be found [here](#).

Scientific Recommendation on Classification of ATMPs (Section 4)

This section includes the scientific recommendation by the CAT on whether medicines based on genes, cells or tissues meet the scientific criteria that define ATMPs. More information on the ATMP classification procedure, including the outcomes of finalised classifications, can be found [here](#).

Scientific Advice (section 5)

This section includes all scientific advice given to companies during the development of an ATMP. Information related to the number of ATMP related scientific advices discussed by CAT can be found in the CAT Monthly reports. Further information on SAWP can be found [here](#).

Pre-Authorisation (section 6)

Paediatric Investigation Plan (PIP)

This section includes the discussion of an ATMP before a formal application for marketing authorisation is submitted. These cases refer for example to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation: in case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

CAT contributes to the evaluation of a Paediatric Investigation Plan (PIPs) for ATMPs by the Paediatric Committee. These PIPs are included in this section of the Agenda.

ITF Briefing meeting in the field of ATMPs

This section refers to briefing meetings of the Innovation Task Force and International co-operations activities of the CAT

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes of meetings with applicants developing ATMPs and of other ITF meetings of interest to the CAT are included in this section of the agenda. Further information on the ITF can be found [here](#).

Priority Medicines (PRIME)

This section includes the new requests for eligibility to PRIME for ATMPs under development, the discussions in CAT of these eligibility requests and the final recommendations for eligibility of ATMPs adopted by CHMP.

CAT will appoint one of its members as the CAT sponsor for each new ATMP eligibility request who will lead the CAT discussion based on the recommendation from the SAWP.

Organisational, regulatory and methodological matters (section 7)

This section includes topics related to regulatory and procedural guidance, CAT workplan, CAT meeting organisation (including CAT membership), planning and reporting, co-ordination with other committees, working parties and scientific advisory groups.

Furthermore, this section refers to the activities of the CAT drafting groups developing scientific guidelines for gene therapy medicinal products and for cell-based medicinal products, cooperation within the EU regulatory network and international regulators as well as direct interaction with interested parties. It also includes topics of scientific interest for the Committee that are not directly related to the work of the CAT drafting groups or CAT associated working parties.

Any other business (section 8)

This section is populated with miscellaneous topics not suitable under the previous headings.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/